Extended Data Fig. 3: Ex vivo T cell responses to SARS-CoV-2-derived HLA class I and HLA-DR T cell epitope compositions in SARS-CoV-2 convalescent and hospitalized COVID-19 patients.
From: SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
a,b, Ex vivo recognition frequency (donors with T cell responses/tested donors) of (a) cross-reactive and (b) SARS-CoV-2-specific ECs by nonexpanded T cells of SARS donors (n = 47) of group 2 analyzed by ex vivo IFN-γ ELISPOT assay. Red bars depict the recognition frequency in ex vivo analyses whereas the white bars indicate the frequency after a 12-d pre-stimulation. c–f, Intensity of T cell responses in terms of calculated spot counts against the (c,d) cross-reactive and (e,f) SARS-CoV-2-specific (c,e) HLA class I and (d, f) HLA-DR ECs, respectively directly ex vivo and after a 12-d expansion in samples of SARS convalescent donors (n = 47). Each spot represents a single donor, paired samples are connected by continuous lines, two-sided Wilcoxon test. Only positive donors are depicted. T cell responses were considered positive when mean spot counts were at least threefold higher than the negative control. g, Characteristics of hospitalized donors (n = 21) analyzed in ex vivo IFN-γ ELISPOT assay. ECMO, extracorporeal membrane oxygenation; n, number; n.a., not available. h, Ex vivo recognition frequency (donors with T cell responses/tested donors) of SARS donors of group 2 compared to hospitalized donors analyzed by ex vivo IFN-γ ELISPOT assay.
